DaVita operates a network of dialysis clinics providing kidney dialysis treatment to patients with end-stage renal disease, one of the largest dialysis providers in the United States. Its clinics provide the ongoing, recurring treatment that patients with kidney failure need multiple times per week indefinitely, since dialysis substitutes for kidney function that patients have permanently lost, creating a highly recurring revenue model tied to its enrolled patient population. DaVita's revenue depends heavily on reimbursement rates from government programs like Medicare, which covers most dialysis patients, along with private insurance reimbursement for patients who have commercial coverage, typically at different rate levels. The company's growth and profitability are sensitive to government reimbursement policy for dialysis treatment, along with the overall prevalence of end-stage renal disease and how many patients require ongoing dialysis care.